Global Disease Control and Prevention Vaccine Market by Type (Live-Attenuated, Inactivated, Recombinant Sub Unit and Toxoid), By Application (Pediatric Vaccine, Adult Vaccine) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
The Global Disease Control and Prevention Vaccine Market size is expected to grow at a CAGR of 8.2% during the forecast period, by 2020, it is projected to reach USD 27.3 billion in value. The growth will primarily be driven by increasing demand for vaccines owing to factors such as changing lifestyle patterns, rise in awareness about diseases, and efforts from governments across the globe to prevent them through vaccination programs and campaigns.
Disease Control and Prevention Vaccines are vaccines used to prevent diseases that can be transmitted from person to person, animal or plant. These vaccines prevent or reduce the severity of an illness. The Disease Control and Prevention vaccines market aims to reduce population morbidity, mortality, disability by controlling infectious diseases such as hepatitis A&B, tetanus, influenza, etc.
On the basis of Types, the market is segmented into Live-Attenuated, Inactivated, and Recombinant Sub Units.
Live-Attenuated Vaccines:
Live-attenuated vaccines are live viruses that have been weakened so they cannot cause infection in humans. The vaccine virus replicates inside the body but does not produce enough of itself to overcome immunity and lead to disease. Live-attenuated vaccines can be given orally (e.g., measles) or by injection (e.g., polio).
Inactivated Vaccines:
Inactivated Vaccines are usually made of whole killed virus and bacteria. They will not cause infection to the vaccinated person as they have been weakened or have no active substances that can stimulate an immune response in the human body. In general, these vaccines cannot be injected into people who have a weak immune system because they may lead to severe infection.
Recombinant Sub Unit Vaccine:
A Recombinant Sub Unit Vaccine is a vaccine composed of recombinant protein subunits. They are used as immunizing agents in the prevention and treatment of diseases caused by bacteria, viruses, or parasites. The proteins that they contain are derived from either natural sources (such as pathogenic organisms) or genetically engineered cells lines. These vaccines can be classified into two types: live attenuated and killed whole cells/subunit preparations.
On the basis of Application, the market is segmented into Pediatric Vaccines and Adult Vaccines.
Pediatric Vaccines:
Disease Control and Prevention Vaccines are used as preventative measures for children against infectious diseases. They aim to immunize, protect and support the health of an individual by providing immunity from illness that can be transmitted through contact with other infected individuals or animals. Disease control vaccines also have a therapeutic effect in cases where prevention is not possible, such as post-exposure or in certain situations like natural disasters.
Adult Vaccines:
Disease Control and Prevention Vaccines in Adult Vaccines are used to protect individuals who may be at risk of contracting specific diseases. These vaccines prevent the contraction of these infectious agents by either inducing immunity or preventing them from attacking healthy cells, tissues, and organ systems.
On the basis of Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The Latin American market is also predicted to register significant gains. The increasing number of Zika virus cases has been driving demand for vaccines that can protect against this infection which may be transmitted via mosquitoes. Countries across the region have seen an increase in birth defects due to pregnant women being exposed to infections like the Tdap vaccine etc., leading them towards higher vaccination coverage through booster doses and other complementary vaccines.
Up Market Research published a new report titled “Disease Control and Prevention Vaccine Market research report which is segmented by Types (Live-Attenuated, Inactivated, Recombinant Sub Unit, and Toxoid), By Applications (Pediatric Vaccine, Adult Vaccine), By Players/Companies GSK, Merck & Co., Inc, Pfizer, Sanofi, AstraZeneca PLC, Sinovac Biotech Ltd, Astellas Pharma Inc, Serum Institute of India Pvt. Ltd, Daiichi Sankyo”.
Report Scope
| Report Attributes | Report Details |
| Report Title | Disease Control and Prevention Vaccine Market Research Report |
| By Type | Live-Attenuated, Inactivated, Recombinant Sub Unit and Toxoid |
| By Application | Pediatric Vaccine, Adult Vaccine |
| By Companies | GSK, Merck & Co., Inc, Pfizer, Sanofi, AstraZeneca PLC, Sinovac Biotech Ltd, Astellas Pharma Inc, Serum Institute of India Pvt. Ltd, Daiichi Sankyo |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 216 |
| Number of Tables & Figures | 152 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Disease Control and Prevention Vaccine Market Report Segments:
The market is segmented by Type Live-Attenuated, Inactivated, Recombinant Sub Unit and Toxoid and By Application Pediatric Vaccine, Adult Vaccine.
Some of the companies that are profiled in this report are:
- GSK
- Merck & Co., Inc
- Pfizer
- Sanofi
- AstraZeneca PLC
- Sinovac Biotech Ltd
- Astellas Pharma Inc
- Serum Institute of India Pvt. Ltd
- Daiichi Sankyo
Disease Control and Prevention Vaccine Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Disease Control and Prevention Vaccine Market
Overview of the regional outlook of the Disease Control and Prevention Vaccine Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Disease Control and Prevention Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Disease Control and Prevention Vaccine Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
- By Type:
1. Live-Attenuated
2. Inactivated
3. Recombinant Sub Unit and Toxoid
7. By Application:1. Pediatric Vaccine
2. Adult Vaccine
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Disease Control and Prevention Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Disease Control and Prevention Vaccine Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Disease Control and Prevention Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Disease Control and Prevention Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Disease Control and Prevention Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Disease Control and Prevention Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Disease Control and Prevention Vaccine Market Size & Forecast, 2018-2028
4.5.1 Disease Control and Prevention Vaccine Market Size and Y-o-Y Growth
4.5.2 Disease Control and Prevention Vaccine Market Absolute $ Opportunity
Chapter 5 Global Disease Control and Prevention Vaccine Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Disease Control and Prevention Vaccine Market Size Forecast by Type
5.2.1 Live-Attenuated
5.2.2 Inactivated
5.2.3 Recombinant Sub Unit and Toxoid
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Disease Control and Prevention Vaccine Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Disease Control and Prevention Vaccine Market Size Forecast by Applications
6.2.1 Pediatric Vaccine
6.2.2 Adult Vaccine
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Disease Control and Prevention Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Disease Control and Prevention Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Disease Control and Prevention Vaccine Analysis and Forecast
9.1 Introduction
9.2 North America Disease Control and Prevention Vaccine Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Disease Control and Prevention Vaccine Market Size Forecast by Type
9.6.1 Live-Attenuated
9.6.2 Inactivated
9.6.3 Recombinant Sub Unit and Toxoid
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Disease Control and Prevention Vaccine Market Size Forecast by Applications
9.10.1 Pediatric Vaccine
9.10.2 Adult Vaccine
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Disease Control and Prevention Vaccine Analysis and Forecast
10.1 Introduction
10.2 Europe Disease Control and Prevention Vaccine Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Disease Control and Prevention Vaccine Market Size Forecast by Type
10.6.1 Live-Attenuated
10.6.2 Inactivated
10.6.3 Recombinant Sub Unit and Toxoid
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Disease Control and Prevention Vaccine Market Size Forecast by Applications
10.10.1 Pediatric Vaccine
10.10.2 Adult Vaccine
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Disease Control and Prevention Vaccine Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Disease Control and Prevention Vaccine Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Disease Control and Prevention Vaccine Market Size Forecast by Type
11.6.1 Live-Attenuated
11.6.2 Inactivated
11.6.3 Recombinant Sub Unit and Toxoid
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Disease Control and Prevention Vaccine Market Size Forecast by Applications
11.10.1 Pediatric Vaccine
11.10.2 Adult Vaccine
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Disease Control and Prevention Vaccine Analysis and Forecast
12.1 Introduction
12.2 Latin America Disease Control and Prevention Vaccine Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Disease Control and Prevention Vaccine Market Size Forecast by Type
12.6.1 Live-Attenuated
12.6.2 Inactivated
12.6.3 Recombinant Sub Unit and Toxoid
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Disease Control and Prevention Vaccine Market Size Forecast by Applications
12.10.1 Pediatric Vaccine
12.10.2 Adult Vaccine
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Disease Control and Prevention Vaccine Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Disease Control and Prevention Vaccine Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Disease Control and Prevention Vaccine Market Size Forecast by Type
13.6.1 Live-Attenuated
13.6.2 Inactivated
13.6.3 Recombinant Sub Unit and Toxoid
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Disease Control and Prevention Vaccine Market Size Forecast by Applications
13.10.1 Pediatric Vaccine
13.10.2 Adult Vaccine
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Disease Control and Prevention Vaccine Market: Competitive Dashboard
14.2 Global Disease Control and Prevention Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GSK
14.3.2 Merck & Co., Inc
14.3.3 Pfizer
14.3.4 Sanofi
14.3.5 AstraZeneca PLC
14.3.6 Sinovac Biotech Ltd
14.3.7 Astellas Pharma Inc
14.3.8 Serum Institute of India Pvt. Ltd
14.3.9 Daiichi Sankyo
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Disease Control and Prevention Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Disease Control and Prevention Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Disease Control and Prevention Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Disease Control and Prevention Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Disease Control and Prevention Vaccine Market Size & Forecast, 2018-2028
4.5.1 Disease Control and Prevention Vaccine Market Size and Y-o-Y Growth
4.5.2 Disease Control and Prevention Vaccine Market Absolute $ Opportunity
Chapter 5 Global Disease Control and Prevention Vaccine Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Disease Control and Prevention Vaccine Market Size Forecast by Type
5.2.1 Live-Attenuated
5.2.2 Inactivated
5.2.3 Recombinant Sub Unit and Toxoid
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Disease Control and Prevention Vaccine Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Disease Control and Prevention Vaccine Market Size Forecast by Applications
6.2.1 Pediatric Vaccine
6.2.2 Adult Vaccine
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Disease Control and Prevention Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Disease Control and Prevention Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Disease Control and Prevention Vaccine Analysis and Forecast
9.1 Introduction
9.2 North America Disease Control and Prevention Vaccine Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Disease Control and Prevention Vaccine Market Size Forecast by Type
9.6.1 Live-Attenuated
9.6.2 Inactivated
9.6.3 Recombinant Sub Unit and Toxoid
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Disease Control and Prevention Vaccine Market Size Forecast by Applications
9.10.1 Pediatric Vaccine
9.10.2 Adult Vaccine
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Disease Control and Prevention Vaccine Analysis and Forecast
10.1 Introduction
10.2 Europe Disease Control and Prevention Vaccine Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Disease Control and Prevention Vaccine Market Size Forecast by Type
10.6.1 Live-Attenuated
10.6.2 Inactivated
10.6.3 Recombinant Sub Unit and Toxoid
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Disease Control and Prevention Vaccine Market Size Forecast by Applications
10.10.1 Pediatric Vaccine
10.10.2 Adult Vaccine
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Disease Control and Prevention Vaccine Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Disease Control and Prevention Vaccine Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Disease Control and Prevention Vaccine Market Size Forecast by Type
11.6.1 Live-Attenuated
11.6.2 Inactivated
11.6.3 Recombinant Sub Unit and Toxoid
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Disease Control and Prevention Vaccine Market Size Forecast by Applications
11.10.1 Pediatric Vaccine
11.10.2 Adult Vaccine
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Disease Control and Prevention Vaccine Analysis and Forecast
12.1 Introduction
12.2 Latin America Disease Control and Prevention Vaccine Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Disease Control and Prevention Vaccine Market Size Forecast by Type
12.6.1 Live-Attenuated
12.6.2 Inactivated
12.6.3 Recombinant Sub Unit and Toxoid
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Disease Control and Prevention Vaccine Market Size Forecast by Applications
12.10.1 Pediatric Vaccine
12.10.2 Adult Vaccine
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Disease Control and Prevention Vaccine Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Disease Control and Prevention Vaccine Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Disease Control and Prevention Vaccine Market Size Forecast by Type
13.6.1 Live-Attenuated
13.6.2 Inactivated
13.6.3 Recombinant Sub Unit and Toxoid
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Disease Control and Prevention Vaccine Market Size Forecast by Applications
13.10.1 Pediatric Vaccine
13.10.2 Adult Vaccine
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Disease Control and Prevention Vaccine Market: Competitive Dashboard
14.2 Global Disease Control and Prevention Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GSK
14.3.2 Merck & Co., Inc
14.3.3 Pfizer
14.3.4 Sanofi
14.3.5 AstraZeneca PLC
14.3.6 Sinovac Biotech Ltd
14.3.7 Astellas Pharma Inc
14.3.8 Serum Institute of India Pvt. Ltd
14.3.9 Daiichi Sankyo
Segments Covered in the Report
The global Disease Control and Prevention Vaccine market has been segmented based on
By Types
The global Disease Control and Prevention Vaccine market has been segmented based on
By Types
- Live-Attenuated
- Inactivated
- Recombinant Sub Unit and Toxoid
- Pediatric Vaccine
- Adult Vaccine
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- GSK
- Merck & Co., Inc
- Pfizer
- Sanofi
- AstraZeneca PLC
- Sinovac Biotech Ltd
- Astellas Pharma Inc
- Serum Institute of India Pvt. Ltd
- Daiichi Sankyo
Our Clients
Related Reports
Some other reports from this category!
